Previously, donor-derived CD7-directed CAR-T cells were used as a bridging treatment for haploidentical stem cell transplantation and significantly improved the long-term disease-free survival rate of patients with r/r T-ALL (9, 10, 13). This evidence concerns the gene CD7 and acute lymphoblastic leukemia.